ELDN on XNAS, Health Care, Eledon Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Net loss of $85M over 12 months with $69.7M cash, but shares are up 28% in a year.
BadShort interest 9.8% of shares, up 4.5% on the prior report
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
expected around 18 Mar 2027 (an estimate: a year ago it reported on 19 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $3.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $77.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$3.9M
30 Jun 2026
–
-$31.6M
31 Mar 2026
–
-$39.0M
31 Dec 2025
–
-$10.4M
30 Sep 2025
–
-$17.5M
30 Jun 2025
–
-$11.2M
31 Mar 2025
–
-$6.5M
30 Sep 2024
–
$77.0M
30 Jun 2024
–
-$44.9M
31 Mar 2024
–
-$10.3M
31 Dec 2023
–
-$9.6M
30 Sep 2023
–
-$10.3M
30 Jun 2023
–
-$9.6M
31 Mar 2023
–
-$10.8M
31 Dec 2022
–
-$58.4M
30 Sep 2022
–
-$10.5M
30 Jun 2022
–
-$9.2M
31 Mar 2022
–
-$9.9M
31 Dec 2021
–
-$8.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$85.0M
-$79.8M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.73
$0.77
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-257%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$69.7M
$93.4M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$69.7M (net cash)
-$93.4M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.36
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
4.9
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-3.2%
153 13F filers vs 158
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
54%
45.5M shares held by 13F filers (30 Sep 2026) of 84.5M outstanding (10 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
9.8%
8.3M shares sold short (30 Oct 2026) of 84.5M outstanding (10 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.5
8.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+4.5%
7.9M shares sold short in the report before, 8.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
70%
70% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
3
3 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
3.0×
3 articles in the last 7 days; its usual week has 1.
Price $1.78 on 20 Nov 2026, +28% over 12 months (12-month range $1.39 to $4.21)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).Institutional holders (13F filers). 153 13F filers reported holding it in the latest 13F quarter, +84% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F funds cutting shares at 42 (30 Sep 2026), 3.7× its normal reading; higher than 100% of its own history.
Two or more unrelated kinds of records unusual within 30 days
14 Aug 2025confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Eledon Pharmaceuticals(ELDN): saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 3.9× the same quarter last year, while it had 6.7M shares sold short in the 30 Sep 2025 report, 56× the same report last year. Two unrelated kinds of activity within 77 days.
Short interest and volume: Short interest spike, became public on 25 Jul 2025
Short interest and volume: Short interest spike, became public on 12 Aug 2025
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2025
Short interest and volume: Short interest spike, became public on 27 Aug 2025
Short interest and volume: Short interest spike, became public on 11 Sep 2025
Short interest and volume: Short interest spike, became public on 25 Sep 2025
Short interest and volume: Short interest spike, became public on 10 Oct 2025
The quarter ended 30 Jun 2025 against the 8 quarters before it.
this quarterearliernormal: 4See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 25 Jul 2025
Eledon Pharmaceuticals had 3.1M shares sold short in the 15 Jul 2025 report, 24× the same report last year.
This period
3.1M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
387K
How far from its usual level
+3.5
Same report last year
129K
History used
1,642 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Eledon Pharmaceuticals had 4.4M shares sold short in the 31 Jul 2025 report, 40× the same report last year.
This period
4.4M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+5.1
Same report last year
108K
History used
1,658 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2025
Eledon Pharmaceuticals saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 3.9× the same quarter last year.
This period
27 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+7.7
Same quarter last year
7
History used
1,642 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Eledon Pharmaceuticals had 5.5M shares sold short in the 15 Aug 2025 report, 54× the same report last year.
This period
5.5M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+6.8
Same report last year
101K
History used
1,673 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2025
Eledon Pharmaceuticals had 4.3M shares sold short in the 29 Aug 2025 report, 37× the same report last year.
This period
4.3M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+4.8
Same report last year
118K
History used
1,687 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2025
Eledon Pharmaceuticals had 5.4M shares sold short in the 15 Sep 2025 report, 65× the same report last year.
This period
5.4M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+6.5
Same report last year
83K
History used
1,704 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2025
Eledon Pharmaceuticals had 6.7M shares sold short in the 30 Sep 2025 report, 56× the same report last year.
This period
6.7M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
413K
How far from its usual level
+8.7
Same report last year
119K
History used
1,719 days
the 30 Sep 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
18 Feb 2025confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Eledon Pharmaceuticals(ELDN): saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 8.5× the same quarter last year, while it had 1.4M shares sold short in the 14 Mar 2025 report, 38× the same report last year. Two unrelated kinds of activity within 91 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2025
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2025
Short interest and volume: Short interest spike, became public on 12 Feb 2025
Short interest and volume: Short interest spike, became public on 27 Feb 2025
Short interest and volume: Short interest spike, became public on 12 Mar 2025
Short interest and volume: Short interest spike, became public on 26 Mar 2025
Short interest and volume: Short interest spike, became public on 10 Apr 2025
Short interest and volume: Short interest spike, became public on 26 Apr 2025
The quarter ended 31 Dec 2024 against the 8 quarters before it.
this quarterearliernormal: 3.5See the evidence (8 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2025
Eledon Pharmaceuticals had 1.0M shares sold short in the 15 Jan 2025 report, 14× the same report last year.
This period
1.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
107K
Typical spread (median absolute deviation)
57K
How far from its usual level
+10.6
Same report last year
71K
History used
1,461 days
the 15 Jan 2025 report24 earlier reportsnormal: 107K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Eledon Pharmaceuticals saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 8.5× the same quarter last year.
This period
34 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
3.5
Typical spread (median absolute deviation)
1
How far from its usual level
+10.2
Same quarter last year
4
History used
1,461 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 3.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Eledon Pharmaceuticals had 1.2M shares sold short in the 31 Jan 2025 report, 20× the same report last year.
This period
1.2M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
113K
Typical spread (median absolute deviation)
62K
How far from its usual level
+11.9
Same report last year
60K
History used
1,477 days
the 31 Jan 2025 report24 earlier reportsnormal: 113K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Feb 2025
Eledon Pharmaceuticals had 1.2M shares sold short in the 14 Feb 2025 report, 22× the same report last year.
This period
1.2M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
118K
Typical spread (median absolute deviation)
71K
How far from its usual level
+10.0
Same report last year
53K
History used
1,491 days
the 14 Feb 2025 report24 earlier reportsnormal: 118K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Mar 2025
Eledon Pharmaceuticals had 1.3M shares sold short in the 28 Feb 2025 report, 34× the same report last year.
This period
1.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
80K
How far from its usual level
+10.3
Same report last year
39K
History used
1,505 days
the 28 Feb 2025 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Mar 2025
Eledon Pharmaceuticals had 1.4M shares sold short in the 14 Mar 2025 report, 38× the same report last year.
This period
1.4M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
136K
Typical spread (median absolute deviation)
93K
How far from its usual level
+9.0
Same report last year
36K
History used
1,519 days
the 14 Mar 2025 report24 earlier reportsnormal: 136K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2025
Eledon Pharmaceuticals had 1.5M shares sold short in the 31 Mar 2025 report, 14× the same report last year.
This period
1.5M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
157K
Typical spread (median absolute deviation)
115K
How far from its usual level
+7.7
Same report last year
107K
History used
1,536 days
the 31 Mar 2025 report24 earlier reportsnormal: 157K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Eledon Pharmaceuticals had 1.8M shares sold short in the 15 Apr 2025 report, 56× the same report last year.
This period
1.8M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
148K
How far from its usual level
+7.2
Same report last year
31K
History used
1,551 days
the 15 Apr 2025 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
26 Nov 2025Short interest and volume change
had 5.0M shares sold short in the 14 Nov 2025 report, 6.8× the same report last year.
Same report last year: 731K; its normal report is 1.5M.
See the evidence
This period
5.0M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
564K
How far from its usual level
+4.2
Same report last year
731K
History used
1,764 days
the 14 Nov 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.3M shares sold short in the 31 Oct 2025 report, 4.5× the same report last year.
Same report last year: 961K; its normal report is 1.5M.
See the evidence
This period
4.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
478K
How far from its usual level
+4.0
Same report last year
961K
History used
1,750 days
the 31 Oct 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.7M shares sold short in the 30 Sep 2025 report, 56× the same report last year.
Same report last year: 119K; its normal report is 1.4M.
See the evidence
This period
6.7M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
413K
How far from its usual level
+8.7
Same report last year
119K
History used
1,719 days
the 30 Sep 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.4M shares sold short in the 15 Sep 2025 report, 65× the same report last year.
Same report last year: 83K; its normal report is 1.3M.
See the evidence
This period
5.4M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+6.5
Same report last year
83K
History used
1,704 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.3M shares sold short in the 29 Aug 2025 report, 37× the same report last year.
Same report last year: 118K; its normal report is 1.3M.
See the evidence
This period
4.3M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+4.8
Same report last year
118K
History used
1,687 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.5M shares sold short in the 15 Aug 2025 report, 54× the same report last year.
Same report last year: 101K; its normal report is 1.2M.
See the evidence
This period
5.5M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+6.8
Same report last year
101K
History used
1,673 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 3.9× the same quarter last year, while it had 6.7M shares sold short in the 30 Sep 2025 report, 56× the same report last year. Two unrelated kinds of activity within 77 days.
See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 25 Jul 2025
Eledon Pharmaceuticals had 3.1M shares sold short in the 15 Jul 2025 report, 24× the same report last year.
This period
3.1M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
387K
How far from its usual level
+3.5
Same report last year
129K
History used
1,642 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Eledon Pharmaceuticals had 4.4M shares sold short in the 31 Jul 2025 report, 40× the same report last year.
This period
4.4M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+5.1
Same report last year
108K
History used
1,658 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2025
Eledon Pharmaceuticals saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 3.9× the same quarter last year.
This period
27 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+7.7
Same quarter last year
7
History used
1,642 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Eledon Pharmaceuticals had 5.5M shares sold short in the 15 Aug 2025 report, 54× the same report last year.
This period
5.5M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+6.8
Same report last year
101K
History used
1,673 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2025
Eledon Pharmaceuticals had 4.3M shares sold short in the 29 Aug 2025 report, 37× the same report last year.
This period
4.3M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+4.8
Same report last year
118K
History used
1,687 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2025
Eledon Pharmaceuticals had 5.4M shares sold short in the 15 Sep 2025 report, 65× the same report last year.
This period
5.4M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
428K
How far from its usual level
+6.5
Same report last year
83K
History used
1,704 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2025
Eledon Pharmaceuticals had 6.7M shares sold short in the 30 Sep 2025 report, 56× the same report last year.
This period
6.7M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
413K
How far from its usual level
+8.7
Same report last year
119K
History used
1,719 days
the 30 Sep 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Aug 2025Institutional holdings change
saw 27 13F filers open a new position in the quarter ended 30 Jun 2025, 3.9× the same quarter last year.
Same quarter last year: 7; its normal quarter is 4.
See the evidence
This period
27 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+7.7
Same quarter last year
7
History used
1,642 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 4.4M shares sold short in the 31 Jul 2025 report, 40× the same report last year.
Same report last year: 108K; its normal report is 1.2M.
See the evidence
This period
4.4M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
418K
How far from its usual level
+5.1
Same report last year
108K
History used
1,658 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 15 Jul 2025 report, 24× the same report last year.
Same report last year: 129K; its normal report is 1.1M.
See the evidence
This period
3.1M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
387K
How far from its usual level
+3.5
Same report last year
129K
History used
1,642 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 15 Apr 2025 report, 56× the same report last year.
Same report last year: 31K; its normal report is 181K.
See the evidence
This period
1.8M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
148K
How far from its usual level
+7.2
Same report last year
31K
History used
1,551 days
the 15 Apr 2025 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.5M shares sold short in the 31 Mar 2025 report, 14× the same report last year.
Same report last year: 107K; its normal report is 157K.
See the evidence
This period
1.5M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
157K
Typical spread (median absolute deviation)
115K
How far from its usual level
+7.7
Same report last year
107K
History used
1,536 days
the 31 Mar 2025 report24 earlier reportsnormal: 157K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 14 Mar 2025 report, 38× the same report last year.
Same report last year: 36K; its normal report is 136K.
See the evidence
This period
1.4M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
136K
Typical spread (median absolute deviation)
93K
How far from its usual level
+9.0
Same report last year
36K
History used
1,519 days
the 14 Mar 2025 report24 earlier reportsnormal: 136K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 28 Feb 2025 report, 34× the same report last year.
Same report last year: 39K; its normal report is 124K.
See the evidence
This period
1.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
80K
How far from its usual level
+10.3
Same report last year
39K
History used
1,505 days
the 28 Feb 2025 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 14 Feb 2025 report, 22× the same report last year.
Same report last year: 53K; its normal report is 118K.
See the evidence
This period
1.2M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
118K
Typical spread (median absolute deviation)
71K
How far from its usual level
+10.0
Same report last year
53K
History used
1,491 days
the 14 Feb 2025 report24 earlier reportsnormal: 118K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 8.5× the same quarter last year, while it had 1.4M shares sold short in the 14 Mar 2025 report, 38× the same report last year. Two unrelated kinds of activity within 91 days.
See the evidence (8 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2025
Eledon Pharmaceuticals had 1.0M shares sold short in the 15 Jan 2025 report, 14× the same report last year.
This period
1.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
107K
Typical spread (median absolute deviation)
57K
How far from its usual level
+10.6
Same report last year
71K
History used
1,461 days
the 15 Jan 2025 report24 earlier reportsnormal: 107K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Eledon Pharmaceuticals saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 8.5× the same quarter last year.
This period
34 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
3.5
Typical spread (median absolute deviation)
1
How far from its usual level
+10.2
Same quarter last year
4
History used
1,461 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 3.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 12 Feb 2025
Eledon Pharmaceuticals had 1.2M shares sold short in the 31 Jan 2025 report, 20× the same report last year.
This period
1.2M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
113K
Typical spread (median absolute deviation)
62K
How far from its usual level
+11.9
Same report last year
60K
History used
1,477 days
the 31 Jan 2025 report24 earlier reportsnormal: 113K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Feb 2025
Eledon Pharmaceuticals had 1.2M shares sold short in the 14 Feb 2025 report, 22× the same report last year.
This period
1.2M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
118K
Typical spread (median absolute deviation)
71K
How far from its usual level
+10.0
Same report last year
53K
History used
1,491 days
the 14 Feb 2025 report24 earlier reportsnormal: 118K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Mar 2025
Eledon Pharmaceuticals had 1.3M shares sold short in the 28 Feb 2025 report, 34× the same report last year.
This period
1.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
124K
Typical spread (median absolute deviation)
80K
How far from its usual level
+10.3
Same report last year
39K
History used
1,505 days
the 28 Feb 2025 report24 earlier reportsnormal: 124K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Mar 2025
Eledon Pharmaceuticals had 1.4M shares sold short in the 14 Mar 2025 report, 38× the same report last year.
This period
1.4M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
136K
Typical spread (median absolute deviation)
93K
How far from its usual level
+9.0
Same report last year
36K
History used
1,519 days
the 14 Mar 2025 report24 earlier reportsnormal: 136K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Apr 2025
Eledon Pharmaceuticals had 1.5M shares sold short in the 31 Mar 2025 report, 14× the same report last year.
This period
1.5M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
157K
Typical spread (median absolute deviation)
115K
How far from its usual level
+7.7
Same report last year
107K
History used
1,536 days
the 31 Mar 2025 report24 earlier reportsnormal: 157K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Eledon Pharmaceuticals had 1.8M shares sold short in the 15 Apr 2025 report, 56× the same report last year.
This period
1.8M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
148K
How far from its usual level
+7.2
Same report last year
31K
History used
1,551 days
the 15 Apr 2025 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Feb 2025Institutional holdings change
saw 34 13F filers open a new position in the quarter ended 31 Dec 2024, 8.5× the same quarter last year.
Same quarter last year: 4; its normal quarter is 3.5.
See the evidence
This period
34 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
3.5
Typical spread (median absolute deviation)
1
How far from its usual level
+10.2
Same quarter last year
4
History used
1,461 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 3.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.2M shares sold short in the 31 Jan 2025 report, 20× the same report last year.
Same report last year: 60K; its normal report is 113K.
See the evidence
This period
1.2M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
113K
Typical spread (median absolute deviation)
62K
How far from its usual level
+11.9
Same report last year
60K
History used
1,477 days
the 31 Jan 2025 report24 earlier reportsnormal: 113K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 15 Jan 2025 report, 14× the same report last year.
Same report last year: 71K; its normal report is 107K.
See the evidence
This period
1.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
107K
Typical spread (median absolute deviation)
57K
How far from its usual level
+10.6
Same report last year
71K
History used
1,461 days
the 15 Jan 2025 report24 earlier reportsnormal: 107K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Dec 2024 report, 24× the same report last year.
Same report last year: 52K; its normal report is 104K.
See the evidence
This period
1.2M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
104K
Typical spread (median absolute deviation)
52K
How far from its usual level
+14.9
Same report last year
52K
History used
1,446 days
the 31 Dec 2024 report24 earlier reportsnormal: 104K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 898K shares sold short in the 13 Dec 2024 report, 14× the same report last year.
Same report last year: 65K; its normal report is 92K.
See the evidence
This period
898K (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
92K
Typical spread (median absolute deviation)
40K
How far from its usual level
+13.7
Same report last year
65K
History used
1,428 days
the 13 Dec 2024 report24 earlier reportsnormal: 92K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 687K shares sold short in the 29 Nov 2024 report, 26× the same report last year.
Same report last year: 26K; its normal report is 77K.
See the evidence
This period
687K (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
77K
Typical spread (median absolute deviation)
39K
How far from its usual level
+10.4
Same report last year
26K
History used
1,414 days
the 29 Nov 2024 report24 earlier reportsnormal: 77K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 731K shares sold short in the 15 Nov 2024 report, 11× the same report last year.
Same report last year: 66K; its normal report is 69K.
See the evidence
This period
731K (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
69K
Typical spread (median absolute deviation)
33K
How far from its usual level
+13.3
Same report last year
66K
History used
1,400 days
the 15 Nov 2024 report24 earlier reportsnormal: 69K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 961K shares sold short in the 31 Oct 2024 report, 18× the same report last year.
Same report last year: 52K; its normal report is 66K.
See the evidence
This period
961K (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
66K
Typical spread (median absolute deviation)
30K
How far from its usual level
+17.9
Same report last year
52K
History used
1,385 days
the 31 Oct 2024 report24 earlier reportsnormal: 66K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 92 entries; narrow the window or the kind of data to see older ones.
Not listed: 111 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001404281
Ticker
ELDN
Domain
eledon.com
Hq location
CA|IRVINE|92612 (1 unverified)
Name
Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)150 records7 Jan 2016 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)693 data points31 Dec 2011 to 10 Nov 2026
SEC Form 4 insider transactions22 records, 64 data points15 Mar 2016 to 13 May 2024
FINRA short interest (twice monthly)417 data points15 Jan 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2956 data points5 Jan 2021 to 20 Nov 2026